monocrotaline has been researched along with pitavastatin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Egashira, K; Iwata, E; Kimura, S; Kishimoto, J; Matoba, T; Miyagawa, M; Nagaoka, K; Nakano, K; Sunagawa, K; Tsujimoto, H | 1 |
| Egashira, K; Funamoto, D; Ichimura, K; Koga, JI; Matoba, T; Nakano, K; Tsutsui, H | 1 |
2 other study(ies) available for monocrotaline and pitavastatin
| Article | Year |
|---|---|
Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension.
Topics: Animals; Cell Line; Cell Proliferation; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Drug Delivery Systems; Fluorescein-5-isothiocyanate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Kaplan-Meier Estimate; Lung; Male; Microscopy, Fluorescence; Monocrotaline; Myocytes, Smooth Muscle; Nanoparticles; NF-kappa B; Nitric Oxide Synthase; Pulmonary Artery; Quinolines; Rats; Rats, Sprague-Dawley; Remission Induction | 2011 |
Nanoparticle-Mediated Targeting of Pitavastatin to Small Pulmonary Arteries and Leukocytes by Intravenous Administration Attenuates the Progression of Monocrotaline-Induced Established Pulmonary Arterial Hypertension in Rats.
Topics: Administration, Intravenous; Animals; Disease Progression; Drug Delivery Systems; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Leukocytes; Male; Monocrotaline; Nanoparticles; Pulmonary Artery; Quinolines; Random Allocation; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2018 |